Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: HRS-7535, HRS7535, GLP-1 receptor agonist 15, EX-A16881, CHEMBL6160879
Safiglipron is a structurally distinct, once-daily oral small-molecule GLP-1 receptor agonist. It has been evaluated in randomized clinical studies in adults with type 2 diabetes and obesity, including phase 2 and phase 3 studies. The compound is identified by the molecular formula C32H31ClFN3O5 and CAS Registry Number 2757506-39-9.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Evidence reviewed supports research use as a reference compound. Published studies report once-daily oral clinical regimens including 15–90 mg in a phase 2 type 2 diabetes study, 30–180 mg in a phase 2 obesity study, and 30, 60, or 90 mg in the OUTSTAND-1 phase 3 study; these are study regimens and not prescribing recommendations. Reliable authoritative sources reviewed did not provide a validated catalog storage condition, aqueous solubility value, or consistently reported terminal half-life for the compound.
Supplementary research context only. Not medical advice or a treatment recommendation.
CAS RN 2757506-39-9; PubChem CID 166094939; molecular formula C32H31ClFN3O5; molecular weight 592.1 g/mol; InChIKey YPJSZRLSBAIGIE-PZGXJGMVSA-N; ChEMBL CHEMBL6160879; IUPAC name 2-[[4-[(3S)-3-(4-chloro-2-fluorophenyl)-2,3-dihydro-1,4-benzodioxin-5-yl]piperidin-1-yl]methyl]-3-[[(2S)-oxetan-2-yl]methyl]benzimidazole-5-carboxylic acid
Safiglipron is listed as a proposed INN in WHO Proposed INN List 134. Published clinical literature identifies safiglipron as HRS-7535. Human studies have used once-daily oral administration, with dose-escalation or titration regimens in some protocols.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention Safiglipron or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.